Pyrukynd
What Pyrukynd is used for
Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.4).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Pyrukynd
- Active substance
- mitapivat
- Disease area
- Genetic Diseases, Inborn; Anemia, Hemolytic
- Medicine group
- Other hematological agents
- ATC code
- B06AX04
- Marketing authorisation holder
- Agios Netherlands B.V.
- Authorised in the EU since
- 2022
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Pyrukynd used for?
Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.4).
What is the active substance in Pyrukynd?
Pyrukynd contains mitapivat.
Who makes Pyrukynd?
The EU marketing authorisation holder is Agios Netherlands B.V..
Is Pyrukynd an orphan medicine?
Yes. Pyrukynd is designated an orphan medicine in the EU, for a rare disease (Genetic Diseases, Inborn; Anemia, Hemolytic).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU